Objective
USA’s top Pharmaceutical company is wanted to understand the reimbursement scenario as well as the payer’s perspective around four different rare solid tumors (HCC, thyroid cancer, GIST, and NETs). They wanted to understanding the current market access scenario of prior approved drugs such as; targeted agents approved for thyroid cancer; Caprelsa, Cometriq, Nexavar, and most recently Lenvima. For NETs – Sutent and Afinitor, and the somatostatin analogues, Sandostatin LAR and Somatuline Autogel. And also wanted to get the prescriber and payer’s perspective on NRST therapies; challenges they do face in terms of disease burden, cost of the product and market access.
Approach
The study involved three major stages:
- Niche and Rare Solid Tumor Patient Journey: Exploration of the patient experience through their unique journey
- Market Access and Payers Perspective: Analysis from the standpoint of market access and insights from payers
- Reimbursement Scenario Analysis: Examination of the reimbursement landscape for niche and rare solid tumor therapies
Questionnaires and discussion guides were methodically created to address identified gaps and issues from secondary research. This approach aimed to obtain comprehensive information for a thorough understanding of the overall market landscape.
Primary research comprised in-depth telephonic interviews with targeted healthcare professionals and regulatory bodies. The objective was to gain insights into drug utilization, market access, and reimbursement scenarios specific to niche and rare solid tumor therapies.
The recommendations and valuable insights for a market entry strategy for a new therapy were derived from the synthesis of primary research findings and the outputs of secondary research.
Results
Patient-Centric Solutions: Identification of key touchpoints in the patient journey, leading to the development of patient-centric solutions that included innovative support programs, educational resources, or improved access pathways to enhance the overall experience for individuals with niche and rare solid tumors
Optimized Market Entry Strategy: Our recommendations for a strategic market entry approach for the new therapy, derived from a deep understanding of market access, payer perspectives, and reimbursement scenarios and included insights on pricing strategies, regulatory considerations, and effective engagement strategies with healthcare professionals
Competitive Advantage Insights: Our analysis of the competitive landscape, provided insights into the strengths and weaknesses of existing therapies in the niche and rare solid tumor space. This further helped our client in positioning their therapy effectively, identifying unique selling propositions and areas where they can offer differentiated value in the market.
